Pooled data from two prospective studies and an expanded-access program (27 participants total) evaluated etuvetidigene autotemcel, a lentiviral gene therapy given as a single infusion after rituximab and reduced-intensity conditioning. The report states overall survival was 96% at both 1 and 5 years, with severe infection rates falling from 2.00 to 0.15 events per person-year and moderate-to-severe bleeding events falling from 2.00 to 0.80 events per person-year after treatment, with no evidence of insertional oncogenesis observed over a median follow-up of 5.7 years.
Loading...